CRISPR Therapeutics AG [CRSP] stock prices are up 4.27% to $42.22 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CRSP shares have gain 2.45% over the last week, with a monthly amount glided 2.93%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
CRISPR Therapeutics AG [NASDAQ: CRSP] stock has seen the most recent analyst activity on February 03, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $65. Previously, Needham reaffirmed its Buy rating on August 06, 2024, and dropped its price target to $84. On August 02, 2024, Rodman & Renshaw initiated with a Buy rating and assigned a price target of $90 on the stock. Wolfe Research initiated its recommendation with a Peer Perform. TD Cowen downgraded its rating to Underperform for this stock on December 11, 2023, but kept the price target unchanged to $30. In a note dated October 17, 2023, Cantor Fitzgerald downgraded an Neutral rating on this stock.
The stock price of CRISPR Therapeutics AG [CRSP] has been fluctuating between $36.52 and $91.10 over the past year. Currently, Wall Street analysts expect the stock to reach $75.71 within the next 12 months. CRISPR Therapeutics AG [NASDAQ: CRSP] shares were valued at $42.22 at the most recent close of the market. An investor can expect a potential return of 79.32% based on the average CRSP price forecast.
Analyzing the CRSP fundamentals
Gross Profit Margin for this corporation currently stands at 0.31% with Operating Profit Margin at -1.65%, Pretax Profit Margin comes in at -1.17%, and Net Profit Margin reading is -1.19%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.12 and Total Capital is -0.15. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 40.97 points at the first support level, and at 39.71 for the second support level. However, for the 1st resistance point, the stock is sitting at 43.04, and for the 2nd resistance point, it is at 43.85.
Ratios To Look Out For
It’s worth pointing out that CRISPR Therapeutics AG [NASDAQ:CRSP]’s Current Ratio is 21.64. Further, the Quick Ratio stands at 21.64, while the Cash Ratio is 2.51. Considering the valuation of this stock, the price to sales ratio is 17.77, the price to book ratio is 1.86.
Transactions by insiders
Recent insider trading involved Kulkarni Samarth, Chief Executive Officer, that happened on Dec 02 ’24 when 15000.0 shares were sold. Chief Executive Officer, Kulkarni Samarth completed a deal on Nov 11 ’24 to sell 30000.0 shares. Meanwhile, General Counsel and Secretary KASINGER JAMES R. sold 1089.0 shares on Oct 14 ’24.
